Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19101541 | 0.90 | GPR84 (0.38) | TSHRPTPN11FFAR4FABP4CNR1 | |
| SCHEMBL10111022 | 0.88 | GPR84 (0.36) | TSHRPTPN11FFAR4FABP4CNR1 | |
| SCHEMBL12924928 | 0.83 | APEX1 (0.42) | TSHRPTPN11FFAR4FABP4CNR1 | |
| SCHEMBL10111020 | 0.83 | GPR84 (0.46) | TSHRFFAR4FABP4PTPN1TDP1 | |
| SCHEMBL25627289 | 0.82 | RARB (0.43) | TSHRPTPN11PLA2G4BRARB | |
| SCHEMBL15341580 | 0.80 | HRH3 (0.32) | PTPN11GAA | |
| SCHEMBL18357046 | 0.79 | RARB (0.45) | PTPN11FFAR4PLA2G4BRARB | |
| SCHEMBL12924927 | 0.79 | MEN1 (0.40) | PTPN11CNR1RARB | |
| SCHEMBL15341578 | 0.78 | THRA (0.33) | FFAR4RARB | |
| SCHEMBL15341582 | 0.78 | TSHR (0.34) | TSHRGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9536633-B2 | Metallic composite and composition thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | CDH1, EPCAM, CD4 | TSHR 3714/4885PTPN11 1694/4885LTB4R 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.